summari report result somewhat
mix maintain oper sale growth outlook rais ep
guidanc full year ep handili beat consensu
estim guidanc ep
beat vs model primarili reflect higher gross margin higher
net incom lower tax rate partli off-set higher opex
total revenu in-lin consensu miss
estim oper growth ex- fx acquisit
cyclophosphamid improv
pharmaceut outperform expect medic
deliveri nutrit under-perform latter partli due
slower expect recoveri hurrican maria impact
maintain underli sale growth guidanc rais
ep outlook year
manag expect sale growth acceler vs
growth improv sequenti new launch
easier comp due hurrican maria last year
mix sale perform busi
outperform revenu beat consensu
estim oper growth
acceler driven solid
perform core busi includ cyclo face
addit competit brevibloc benefit
competit suppli issu howev medic deliveri revenu
miss consensu estim
oper growth deceler flat
manag attribut weak two key issu slower
expect custom share gain larg volum parenter
compani expect improv continu suppli
issu small volum parenter also improv
continu nutrit sale fell shi
consensu estim oper
growth fall flat compani note
constraint slower expect could take
sever quarter recov
rais ep guidanc compani increas full
year ep guidanc
midpoint guidanc rang ep outlook increas
suggest vast major rais reflect
beat given bax earn track record continu see
ep upsid guid ep
impli ep
continu next page
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
adjust spin-off baxalta
compani prioriti stock list
compani data secur llc estim reuter
continu previou page
maintain oper sale growth outlook compani continu expect full year
ex-fx sale growth oper sale growth guidanc assum two new gener
cyclo competitor one alreadi approv new brevibloc competitor start late sequenti
improv medic deliveri nutrit busi compani lower
sale growth expect medic deliveri nutrit rais outlook
pharmaceut growth report basi sale growth expect lower vs previou
due lower fx tailwind fact expect fx becom headwind year
vs tailwind
face sever potenti headwind estim fx becom headwind
would expect much impact year drag top-lin
unavoid would expect absorb impact bottom-lin oper line
guid net incom year current model line fall
although provid outlook next year term tax rate expect increas
year next year estim repres ep headwind
could off-set headwind strong margin improv possibl increas share
repurchas compani look lower tax rate beyond
metricswfconsensusrevenu renal therapi therapi deliveri deliveri surgeri surgeri growth wth ex-fx otherwis note renal factset revenu profit compani report secur llc estim factset visibl alpha explicitli state consensu visibl alpha may vari base broker contribut medic technolog
price target nc
price target base equal weight ev/ebtida dcf price-to-earnings risk
thesi includ unexpect competit headwind could slow restructur effort signific delay new
believ acceler sale growth expand oper margin consist deliv
reliabl low double-digit ep growth strong balanc sheet could enhanc long-term growth
baxter global medic product compani focus hospit product renal compani
report sale billion ex-fx growth
statement fy end dec million except per share revenu report structur -- hospit product gross gross tsa transit svc agreement sg total oper oper net interest incom expens incom expens total non-op incom expens pre-tax incom tax expens net adjust share outstand marginsgross ex-msa changetot share compani report secur llc estim
